| Autor: |
Elshamy, Amira M., Salem, Ola M., Safa, Mohamed A. E., Barhoma, Ramez A. E., Eltabaa, Eman F., Shalaby, Amany M., Alabiad, Mohamed A., Arakeeb, Heba M., Mohamed, Hoda A. |
| Předmět: |
|
| Zdroj: |
Journal of Biochemical & Molecular Toxicology; Mar2022, Vol. 36 Issue 3, p1-10, 10p |
| Abstrakt: |
Vincristine is a chemotherapy drug that belongs to the vinca alkaloids group. It is used for treatment of hematologic malignancies and several solid tumors. Vincristine‐induced peripheral neuropathy is a major dose‐limiting side effect. Coenzyme Q10 (Co Q10), an essential component of the mitochondrial electron transport chain, participates in energy production. It is a powerful fat‐soluble antioxidant and also exerts anti‐inflammatory effects. Therefore, this study was aimed to focus on the mechanistic insights of vincristine‐induced peripheral neuropathy in addition to shedding the light on the modulatory effect of Co Q10. Twenty‐eight rats were randomly divided into four groups. Peripheral neuropathy was induced by intraperitoneal injection of vincristine (0.1 mg/kg body weight). Co Q10 was injected intraperitoneally (10 mg/kg body weight) for 24 days. Sciatic nerve MDA, TAC, GSH, 8‐OHdG, TNF‐α, IL‐1β, and NF‐κB levels were assessed. Gene expression of SARM1 and Nrf2 was also assessed. Serum neurofilament light chain was immunoassayed, in addition to the behavioral assessment. Co Q10 significantly improved oxidative stress and inflammatory biomarkers. It also decreased serum NFL levels. It enhanced Nrf2 and decreased SARM1 gene expression. Histopathological findings proved the biochemical and molecular findings. Our results support Co Q10 as a potential protective agent against vincristine‐induced peripheral neuropathy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text